FIELD: biotechnology.
SUBSTANCE: methods of treatment and prophylactic treatment of hemophilia A in a subject are presented, which involve administering a chimeric polypeptide to the subject containing factor VIII (FVIII) protein and von Willebrand factor (VWF) protein. In this case, the chimeric polypeptide is administered intravenously in one or more doses ranging from 45 IU/kg to 55 IU/kg, and the interval between dosing is at least 7 days, where the FVIII polypeptide is linked to the VWF fragment using a covalent bond.
EFFECT: invention is used to treat severe hemophilia A in a subject.
14 cl, 6 dwg, 19 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HIGH GLYCATED FUSED PROTEIN BASED ON HUMAN BLOOD COAGULATION FACTOR VIII, METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2016 |
|
RU2722374C1 |
| PHARMACEUTICAL COMPOSITIONS OF PEGYLATED LIPOSOMES AND COAGULATION FACTORS | 2015 |
|
RU2737291C2 |
| PREPARATION CONTAINING VIII FACTOR AND VON WILLEBRAND FACTOR PEPTIDES | 2015 |
|
RU2714154C2 |
| GLYCOSYLATED FUSED PROTEINS VWF WITH IMPROVED PHARMACOKINETICS | 2017 |
|
RU2782212C2 |
| PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING AND/OR TREATING A DISEASE THAT DEVELOPS OR PROGRESSES AS A RESULT OF REDUCING OR LOSING ACTIVITY OF THE BLOOD COAGULATION FACTOR VIII AND/OR ACTIVATED COAGULATION FACTOR VIII | 2015 |
|
RU2721910C2 |
| IMPROVED FVIII FUSION PROTEIN AND ITS USE | 2019 |
|
RU2789085C2 |
| RECOVERED NUCLEIC ACID WHICH CODES FVIII-BDD-BASED FUSION PROTEIN AND HETEROLOGOUS SIGNAL PEPTIDE, AND USE THEREOF | 2022 |
|
RU2818229C2 |
| NUCLEIC ACID MOLECULES AND WAYS OF USING THEM | 2018 |
|
RU2819144C2 |
| USING OF LENTIVIRAL VECTORS EXPRESSING FACTOR VIII | 2019 |
|
RU2803163C2 |
| IMPROVEMENT OF CLINICAL PARAMETERS THROUGH FACTOR VIII EXPRESSION | 2019 |
|
RU2799048C2 |
